SLC5A2 and atrial fibrillation: SGLT2 inhibitors reduced AF risk by 37% (RR 0.63; 95% CI: 0.45–0.87; p < 0.05); AF/AFL risk by 34% (RR 0.66; 95% CI: 0.49–0.90; p < 0.05).